Roche and Hansoh Sign Cancer Drug Licensing Deal Worth Up to $15 Billion
Roche entered a collaboration and licensing agreement with China's Hansoh for a portfolio of targeted cancer drugs. The deal could exceed $15 billion.
Swiss drugmaker Roche BX:RHO has entered a collaboration and licensing agreement with China’s Hansoh HKEX:3692 covering a portfolio of targeted cancer drugs. The deal could exceed $15 billion. The agreement is the latest in a wave of deals between Chinese biotech companies and global drugmakers.